Purpose: This pilot study aimed to provide basic data on intravenous infusion nursing by analyzing the infusion rate in the cephalic and median cubital veins depending on the height of the infusion bag and inner diameter of the peripheral venous catheter (PVC).

Methods: While infusing 0.9% normal saline at 22 °C (room temperature) into elbow cephalic and median cubital veins, the infusion rate may be controlled by adjusting the fluid height and PVC diameter. To assess the validity of the laminar flow assumption, the study estimated the Reynolds number (Re) using the velocity obtained by applying Bernoulli's equation considering the friction coefficient.

Results: At a constant fluid height, the infusion rate increased with increasing PVC diameter. At a constant PVC diameter, the infusion rate increased with increasing fluid height. In a comparison between the cephalic and median cubital veins at constant fluid height and PVC diameter, the solution was infused at a higher rate into the cephalic vein, which was under lower venous pressure.

Conclusion: The analysis of the infusion rate according to fluid height and PVC diameter provided basic data on intravenous infusion nursing. The results are expected to provide evidence for the standardization of intravenous infusion nursing.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684996PMC
http://dx.doi.org/10.2147/JMDH.S409050DOI Listing

Publication Analysis

Top Keywords

infusion rate
24
fluid height
20
pvc diameter
20
cephalic median
16
median cubital
16
cubital veins
16
rate cephalic
12
intravenous infusion
12
infusion nursing
12
height pvc
12

Similar Publications

The introduction of anti-tumor necrosis factor-α (anti-TNF-α) agents, particularly infliximab (IFX) and adalimumab (ADA), has significantly expanded the therapeutic arsenal for inflammatory bowel disease (IBD). While these biologics have demonstrated substantial efficacy, they are associated with a spectrum of potential adverse events (AEs). This study aims to evaluate and document these AEs to facilitate optimal patient selection and monitoring strategies of patients undergoing these therapies.

View Article and Find Full Text PDF

: Cerebral intra-arterial chemotherapy (CIAC) has been demonstrated to achieve tumoricidal concentrations in cerebral tumour cells that are otherwise unachievable due to the presence of the blood-brain barrier. In this study, we sought to analyze the safety of CIAC in a cohort of patients treated at the Centre intégré universitaire de santé et de services sociaux de l'Estrie-Centre hospitalier universitaire de Sherbrooke (CIUSSS-CHUS). : Treatments consisted of monthly CIAC.

View Article and Find Full Text PDF

: Autologous platelet-rich plasma (PRP) transfusions are a relatively new treatment method used in different fields of medicine, including the field of reproductive medicine. One of the applications of these concentrated platelet infusions is the treatment of endometrial receptivity, which is a key factor for embryo implantation. There are implications that PRP infusions can lead to increased endometrial thickness, endometrial receptivity, and significantly elevated clinical pregnancy rates.

View Article and Find Full Text PDF

Background: PD-L1 and VEGF blockade with atezolizumab plus bevacizumab has been shown to improve survival in unresectable hepatocellular carcinoma. TIGIT is an immune checkpoint regulator implicated in many cancers, including unresectable hepatocellular carcinoma. Here, we evaluate the clinical activity and safety of the addition of tiragolumab, an anti-TIGIT monoclonal antibody, to atezolizumab plus bevacizumab.

View Article and Find Full Text PDF

B-cell non-Hodgkin lymphoma (B-NHL) is a highly heterogeneous group of lymphopoietic malignancies that account for 85% to 90% of all non-Hodgkin lymphomas. In recent years, CD19 Chimeric antigen receptor T (CAR T) cell immunotherapy has significantly improved the cure rate of B-NHL patients, but there are still some patients who cannot achieve remission after treatment, or relapse after remission. Therefore, it is of great importance to overcome the drug resistance of CD19 CAR T cells after B-NHL treatment and reduce the recurrence rate of CD19 CAR T cells after B-NHL treatment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!